Investors expect Sanofi (NASDAQ:SNY)’s quarterly earnings on April, 26., according to Faxor. Last year’s earnings per share was $0.79, while now analysts expect change of 0.00 % from current $0.79 earnings per share. If SNY’s EPS is $0.79 the profit will reach $1.97B for 13.98 P/E. Wall Street now sees 25.40 % EPS growth despite Sanofi previous quarter’s EPS of $0.63. Ticker’s shares touched $44.19 during the last trading session after 0.55% change.Currently Sanofi is uptrending after 8.45% change in last March 27, 2018. SNY has 684,162 shares volume. The stock outperformed the S&P500 by 4.08%.

Sanofi researches, develops, manufactures, and markets therapeutic solutions.The firm is worth $110.17 billion. The firm operates in two divisions, Pharmaceuticals and Vaccines.The P/E ratio is 22.78. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

For more Sanofi (NASDAQ:SNY) news published briefly go to: Nasdaq.com, Nasdaq.com, Benzinga.com, Seekingalpha.com or Nasdaq.com. The titles are as follows: “Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion – Nasdaq” published on March 04, 2019, “Why Sangamo Therapeutics Lost 22.9% of Its Value in February – Nasdaq” on March 04, 2019, “Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings (March 17-23) – Benzinga” with a publish date: March 16, 2019, “FDA OKs expanded label for Sanofi’s Soliqua – Seeking Alpha” and the last “European ADRs Move Higher in Tuesday Trading – Nasdaq” with publication date: March 05, 2019.